One of the earliest studies with small-molecule MDM2 inhibitors in CLL showed that Nutlin-3a induced p53-mediated apoptosis in a majority of primary samples from untreated patients; all resistant samples had TP53 mutations [9]. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.